Works matching IS 03407004 AND DT 2020 AND VI 69 AND IP 1


Results: 16
    1
    2
    3

    Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.

    Published in:
    Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 127, doi. 10.1007/s00262-019-02446-1
    By:
    • Ozaki, Yuki;
    • Muto, Satoshi;
    • Takagi, Hironori;
    • Watanabe, Masayuki;
    • Inoue, Takuya;
    • Fukuhara, Mitsuro;
    • Yamaura, Takumi;
    • Okabe, Naoyuki;
    • Matsumura, Yuki;
    • Hasegawa, Takeo;
    • Ohsugi, Jun;
    • Hoshino, Mika;
    • Shio, Yutaka;
    • Tanaka, Daisuke;
    • Nanamiya, Hideaki;
    • Imai, Jun-ichi;
    • Isogai, Takao;
    • Watanabe, Shinya;
    • Suzuki, Hiroyuki
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15

    Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody.

    Published in:
    Cancer Immunology, Immunotherapy, 2020, v. 69, n. 1, p. 15, doi. 10.1007/s00262-019-02431-8
    By:
    • Shibaki, Ryota;
    • Murakami, Shuji;
    • Matsumoto, Yuji;
    • Yoshida, Tatsuya;
    • Goto, Yasushi;
    • Kanda, Shintaro;
    • Horinouchi, Hidehito;
    • Fujiwara, Yutaka;
    • Yamamoto, Nobuyuki;
    • Kusumoto, Masahiko;
    • Yamamoto, Noboru;
    • Ohe, Yuichiro
    Publication type:
    Article
    16